Redx Pharma (GB:REDX) has released an update.
Redx Pharma, a biotech firm specializing in fibrotic disease and cancer treatments, has reported share purchases by two key executives. Chief Financial Officer Peter Collum and General Counsel Claire Solk have acquired a significant number of ordinary shares, signaling potential insider confidence in the company’s future.
For further insights into GB:REDX stock, check out TipRanks’ Stock Analysis page.
